Hsiangfeng Tsai
Psychiatric/Mental Health · Vancouver, WANPI 1164806634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 24.4% of the total. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$605
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$593
- Alkermes, Inc.$578
- E.r. Squibb & Sons, L.L.C.$330
- Supernus Pharmaceuticals, Inc.$255
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,51599%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 59 | $1,115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $605 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $593 |
| Alkermes, Inc. | 37 | $578 |
| E.r. Squibb & Sons, L.L.C. | 11 | $330 |
| Supernus Pharmaceuticals, Inc. | 8 | $255 |
| Lundbeck LLC | 13 | $247 |
| Axsome Therapeutics, Inc. | 11 | $236 |
| AbbVie | 12 | $172 |
| Sunovion Pharmaceuticals Inc. | 12 | $169 |
| Johnson & Johnson | 1 | $96 |
| Corium, LLC | 8 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY ASIMTUFII$124
- ABILIFY MAINTENA$124
- REXULTI$110
How this compares
$4,573 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 52 | $167,101 |
| LybalviOlanzapine/Samidorphan Malate | 47 | $75,299 |
| Abilify MaintenaAripiprazole | 21 | $61,148 |
| PerserisRisperidone | 23 | $56,421 |
| VraylarCariprazine Hcl | 34 | $42,210 |
| Risperidone ErRisperidone Microspheres | 33 | $26,321 |
| Risperdal ConstaRisperidone Microspheres | 20 | $20,774 |
| Paliperidone ErPaliperidone | 27 | $12,201 |
| Clozapine | 117 | $9,115 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,732 |
| Prazosin Hcl | 158 | $5,647 |
| Divalproex Sodium ErDivalproex Sodium | 42 | $5,104 |
| Duloxetine Hcl | 135 | $5,047 |
| Fluphenazine Decanoate | 41 | $4,049 |
| Quetiapine Fumarate | 214 | $2,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $96 | $187,87672 claims |
| Alkermes, Inc.Lybalvi | $578 | $75,29947 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,115 | $61,14821 claims |
| AbbVieVraylar | $172 | $42,21034 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $605 | $5,73215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Vancouver
- Brendan RoeVancouver$18K
- Rhonda RowanVancouver$10K
- John JohnsonVancouver$8K
- Nwamaka EmeruemVancouver$8K
- David CaliffVancouver$4K
- Cailin JarrellVancouver$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.